Amsterdam - Delayed Quote EUR

Benevolent AI (BAIW.AS)

0.3700

0.0000

(0.00%)

As of July 12 at 10:00:00 PM GMT+2. Market Open.

We're Keeping An Eye On BenevolentAI's (AMS:BAI) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 24 days ago

BAIVF
BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission

LONDON, December 11, 2024--Regulatory News: BenevolentAI ("the Company"), a pioneer in integrating artificial intelligence with biopharmaceutical development, today unveils a major strategic overhaul to return the Company to its founding TechBio mission. These changes mark a return to the Company’s foundational strengths, refocusing efforts on core technologies and innovation to better develop transformative drug discovery and development solutions. In parallel, and to support this, the Company

Business Wire last month

BAIVF
BenevolentAI Appoints Kenneth Mulvany as Executive Chairman

LONDON, October 17, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery and development, today announces the appointment of Kenneth (Ken) Mulvany as Executive Chairman. Dr. Joerg Moeller is stepping down as Chief Executive Officer with immediate effect.

Business Wire 2 months ago

BAIVF
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024

LONDON, October 10, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology Officer, will hold a presentation titled "Building Trust and Explainability in using AI in Drug Discovery" at BioTechX Europe in Basel on 10 October 2024 at 11:45 AM CET. The presentation will discuss how explainable artificial intelligence can increase transparency in drug dis

Business Wire 3 months ago

BAIVF
BenevolentAI First Half 2024 Earnings: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)

BenevolentAI ( AMS:BAI ) First Half 2024 Results Key Financial Results Net loss: UK£24.8m (loss narrowed by 32% from 1H...

Simply Wall St. 3 months ago

BAIVF
BenevolentAI Interim Results for the Six Months Ended 30 June 2024

LONDON, September 19, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or "the Company" or "the Group") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2024.

Business Wire 3 months ago

BAIVF
BenevolentAI Notice of Interim Results

LONDON, September 06, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months ended 30 June 2024, on Thursday 19 September 2024.

Business Wire 4 months ago

BAIVF
BenevolentAI S.A.'s (AMS:BAI) market cap up €43m last week, benefiting both individual investors who own 28% as well as insiders

Key Insights The considerable ownership by individual investors in BenevolentAI indicates that they collectively have a...

Simply Wall St. 4 months ago

BAIVF
Will BenevolentAI (AMS:BAI) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

BAIVF
BenevolentAI: Appointment of Adviser

LONDON, July 04, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company’s Financial and Capital Markets Adviser, with immediate effect.

Business Wire 6 months ago

BAIVF
BenevolentAI: Leadership Team Change

LONDON, July 03, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors.

Business Wire 6 months ago

BAIVF
BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio

LONDON, June 25, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI.

Business Wire 6 months ago

BAIVF
BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit

LONDON, June 19, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming Morgan Stanley 3rd Annual Life Sciences AI Summit, 26-27 June 2024, in New York, US.

Business Wire 6 months ago

BAIVF
BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference

LONDON, June 04, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will participate in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, 11-13 June 2024 in Miami, US.

Business Wire 7 months ago

BAIVF
BenevolentAI S.A. (AMS:BAI) Is Expected To Breakeven In The Near Future

With the business potentially at an important milestone, we thought we'd take a closer look at BenevolentAI S.A.'s...

Simply Wall St. 7 months ago

BAIVF
BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected

LONDON, May 15, 2024--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI.

Business Wire 7 months ago

BAIVF
BenevolentAI: Result of Annual General Meeting

LONDON, May 02, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery announces that all resolutions proposed at its Annual General Meeting held today were duly passed. The voting results will be made available shortly on the Company’s website (www.benevolent.com/investors/general-meetings/), where the full documentation regarding the AGM can also be found.

Business Wire 8 months ago

BAIVF
BenevolentAI Provides an Update on Its Business Priorities

LONDON, April 23, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities.

Business Wire 8 months ago

BAIVF
BenevolentAI: Publication of the Revised Agenda for the 2024 AGM

LONDON, April 17, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of the Revised Agenda for its Annual General Meeting set to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the "2024 AGM") (the "Revised Agenda").

Business Wire 8 months ago

BAIVF
Proposed Changes to BenevolentAI’s Board Composition

LONDON, April 15, 2024--Regulatory News: BenevolentAI (or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that following extensive discussions with Mr. Kenneth Mulvany, founder and former Chairman of BenevolentAI Limited and a Non-Executive Director of BenevolentAI, several resolutions will be put forward at the Company’s upcoming Annual General Meeting ("AGM") relating to the future membership of the board of the

Business Wire 8 months ago

BAIVF

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Benevolent AI (BAIW.AS)

We're Keeping An Eye On BenevolentAI's (AMS:BAI) Cash Burn Rate

BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission

BenevolentAI Appoints Kenneth Mulvany as Executive Chairman

BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024

BenevolentAI First Half 2024 Earnings: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)

BenevolentAI Interim Results for the Six Months Ended 30 June 2024

BenevolentAI Notice of Interim Results

BenevolentAI S.A.'s (AMS:BAI) market cap up €43m last week, benefiting both individual investors who own 28% as well as insiders

Will BenevolentAI (AMS:BAI) Spend Its Cash Wisely?

BenevolentAI: Appointment of Adviser

BenevolentAI: Leadership Team Change

BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio

BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit

BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference

BenevolentAI S.A. (AMS:BAI) Is Expected To Breakeven In The Near Future

BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected

BenevolentAI: Result of Annual General Meeting

BenevolentAI Provides an Update on Its Business Priorities

BenevolentAI: Publication of the Revised Agenda for the 2024 AGM

Proposed Changes to BenevolentAI’s Board Composition